Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has the Profitability Rank of 9. It has a higher profitability and may stay that way.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:
1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Profitability Rank vs Drug Manufacturers Industry
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has the Profitability Rank of 9. It has a higher profitability and may stay that way.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Good or high score = 8 or 9
Bad or low score = 0 or 1
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has an F-score of 4 indicating the company's financial situation is typical for a stable company.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Good Sign:
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents operating margin is expanding. Margin expansion is usually a good sign.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) has a Profitability Rank of 9 as of Jun. 2026. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. This is 50% above median its historical median of 6.00. Over the past decade, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Profitability Rank has ranged from 4.00 to 9.00.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Profitability Rank too high?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' current Profitability Rank of 9 is 50% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 9.00. Overall, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Profitability Rank compare to ZTS and UTHR?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Profitability Rank of 9 can be compared against companies in the Drug Manufacturers industry. Historically, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' own Profitability Rank has ranged from 4.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Profitability Rank for a Drug Manufacturers company?
A good Profitability Rank depends on the Drug Manufacturers industry context. However, Profitability Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Profitability Rank mean?
A high Profitability Rank can signal that a stock is expensive relative to its fundamentals. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current Profitability Rank is 9, which is 50% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock overvalued right now?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) is currently considered Significantly Overvalued. The stock's GF Value™ is E£4.54, compared to a current price of E£6.28 — trading 38.3% above its estimated fair value. The current Profitability Rank is 9, which is 50% above median its 10-year median of 6.00. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Profitability Rank calculated?
Profitability Rank is calculated from a company's financial statements. For Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA), the current Profitability Rank is 9 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock appears to be overvalued.
The current stock price of E£6.28 is trading 38.3% above its estimated GF Value™ of E£4.54.
GuruFocus considers Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents to be Significantly Overvalued.
Key valuation signals for CAI:RMDA:
Profitability Rank: 9 (50% above median its 10-year median of 6.00)
GF Value™: E£4.54 vs. price of E£6.28 (38.3% above fair value)
No single metric tells the full story. See the CAI:RMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use; manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals; importing pharmaceutical reagents and raw materials necessary for serving the its purposes without trading; producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others; and producing food supplements for human use for others and by others. It has two segments: production and selling of pharmaceutical products, which generates maximum revenue; and manufacturing for others (Toll manufacturing).
84GF Score
Get the complete analysis for CAI:RMDA
Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:RMDA has been successfully added to your 
